Skip to main content

Advertisement

Table 1 Demographic data of evaluable NMOSD and MS patients during the follow-up period

From: Comparison between the cranial magnetic resonance imaging features of neuromyelitis optica spectrum disorder versus multiple sclerosis in Taiwanese patients

  NMOSD (n = 25) MS (n = 29) P -value
Age at 1st attack (years old) 37.8 ± 13.6 33.7 ± 9.2 0.194
Male: female 3 : 22 7 : 22 0.310
Symptoms during the study period
  Weakness (%) 25(100) 20(69) 0.002*
  Sensory disturbance (%) 25(100) 23(79) 0.025*
  Blurred vision (%) 25(100) 19(66) 0.001*
  Consciousness change (%) 8(32) 1(3) 0.008*
  Diplopia (%) 2(8) 10(34) 0.025*
  Dysphagia/dysarthria (%) 0(0) 7(24) 0.012*
  Urine/stool retention (%) 12(48) 3(10) 0.003*
  Hiccup (%) 2(8) 0(0) 0.210
  Polyuria >3000 ml/day (%) 2(8) 0(0) 0.210
  Endocrinopathy (%) 7(28) 3(10) 0.160
  Diabetes mellitus (%) 3(12) 2(7) 0.653
  Thyroid dysfunction (%) 4(16) 1(3) 0.170
  Respiratory failure (%) 5(20) 0(0) 0.017*
  Expired (%) 2(8) 0(0) 0.210
Follow-up duration (months) 129.0 ± 69.5 77.6 ± 64.2 0.007*
Annual relapse rate (%) 65.0 ± 50.1 54.4 ± 47.3 0.427
AQP4 antibody (%) 25 (100) 0 (0) 0.000*
Long term steroid, IST and DMT
  Steroid 22 (88) 8 (28) 0.000*
  Steroid + Azathioprine 5 (20) 0 (0) 0.017*
  Interferon beta 2 (8) 10 (35) 0.025*
  Copaxone 1 (4) 1 (3) 1.000
  Fingolimod 0 (0) 9 (31) 0.002*
  1. NMOSD: neuromyelitis optica spectrum disorder; MS: multiple sclerosis; IST: immunosuppressant therapy; DMT: disease modifying therapy.
  2. *Statistically significant difference between NMOSD and MS.
  3. Conscious change due to sepsis, epilepsy, shock, or other brain structure lesions.